Maternal hypertensive disorders in pregnancy and early childhood cardiometabolic risk factors: The Generation R Study

Dionne V. Gootjes1,2*, Anke G. Posthumus1,2, Vincent W. V. Jaddoe2,3, Bas B. van Rijn1,2, Eric A. P. Steegers1,2

1 Division of Obstetrics and Fetal Medicine, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Rotterdam, The Netherlands, 2 Generation R Study Group, Erasmus University Medical Centre, Rotterdam, The Netherlands, 3 Department of Paediatrics, Erasmus University Medical Centre, Rotterdam, The Netherlands

* d.gootjes@erasmusmc.nl

Abstract

The objective of this study was to determine the associations between hypertensive disorders of pregnancy and early childhood cardiometabolic risk factors in the offspring. Therefore, 7794 women from the Generation Rotterdam Study were included, an ongoing population-based prospective birth cohort. Women with a hypertensive disorder of pregnancy were classified as such when they were affected by pregnancy induced hypertension, pre-eclampsia or the haemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome during pregnancy. Early childhood cardiometabolic risk factors were defined as the body mass index at the age of 2, 6, 12, 36 months and 6 years. Additionally, it included systolic blood pressure, diastolic blood pressure, total fat mass, cholesterol, triglycerides, insulin and clustering of cardiometabolic risk factors at 6 years of age. Sex-specific differences in the associations between hypertensive disorders and early childhood cardiometabolic risk factors were investigated. Maternal hypertensive disorders of pregnancy were inversely associated with childhood body mass index at 12 months (confounder model: -0.15 SD, 95% CI -0.27; -0.03) and childhood triglyceride at 6 years of age (confounder model: -0.28 SD, 95% CI -0.45; -0.10). For the association with triglycerides, this was only present in girls. Maternal hypertensive disorders of pregnancy were not associated with childhood body mass index at 2, 6 and 36 months. No associations were observed between maternal hypertensive disorders of pregnancy and early childhood cardiometabolic risk factors at 6 years of age. Our findings do not support an independent and consistent association between maternal hypertensive disorders of pregnancy and early childhood cardiometabolic risk factors in their offspring. However, this does not rule out possible longer term effects of maternal hypertensive disorders of pregnancy on offspring cardiometabolic health.
Introduction

Hypertensive disorders of pregnancy (HDP) complicate up to 10% of pregnancies and represent a significant cause of morbidity and mortality in both mother and child [1–3]. After having a HDP, there is an approximately twofold risk of developing cardiovascular or cerebrovascular disease [4–6]. In contrast, conflicting data exist on the associations with cardiometabolic risk factors in the offspring [7–11].

A number of mechanism are proposed, through which HDP may affect cardiometabolic risk factors in the offspring. First, there may be alterations in fetal vasculature and cardiac development due to exposure to maternal angiogenic factors during pregnancy [12, 13]. Second, relative fetal undernutrition due to maternal vasoconstriction may lead to adjusted fetal programming, which has a negative effect on cardiometabolic health in the offspring [14–16]. Thirdly, shared maternal and fetal genetic risk and lifestyle factors for cardiometabolic risk factors may explain the association [17–19]. Lastly, spontaneous or iatrogenic preterm birth and the associated low birthweight may mediate the association with increased cardiometabolic risk factors in the offspring [20–22].

The association between childhood cardiometabolic risk factors and the cardiometabolic profile in adult life has been well established [23, 24]. Early identification of children at risk for the development of such an adverse profile is therefore important to potentially mitigate these risks [25]. There are no consistent results with regard to an increased cardiometabolic risk for young offspring that is prenatally exposed to HDP. Therefore, we wish to add to the evidence [13, 26–29]. Thus, the aim of this study is to investigate the associations between maternal HDP and early childhood cardiometabolic risk factors, in a large and multi-ethnic population-based cohort.

Methods

Population and study design

This prospective cohort study was embedded in the Generation R Study, a prospective population-based cohort in Rotterdam, the Netherlands [30]. Pregnant women were eligible for the study if they had an expected delivery date from April 2002 until January 2006 and were living in the study area in the city of Rotterdam. The following pregnancies were excluded from the analysis: twin pregnancies, terminated pregnancies, intra-uterine fetal demise and pregnancies without data on maternal hypertensive disorders or early childhood cardiometabolic risk factors (Fig 1). The study protocol was approved by the Medical Ethical Committee of Erasmus Medical Centre, Rotterdam (MEC 198.782/2001/31). Written informed consent was obtained from all participants.

Hypertensive disorders of pregnancy

Women with a HDP were classified as such when they were affected by gestational hypertension (GH), pre-eclampsia (PE) or the haemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome during pregnancy. Information on physician-diagnosed GH, PE or HELLP was retrieved from hospital charts [31]. The diagnosis was determined based on the criteria of the International Society for the Study of Hypertension in Pregnancy and according to those of the American College of Obstetricians and Gynaecologists [32]. GH was defined as a systolic blood pressure ≥140 mmHg or a diastolic blood pressure ≥90 mmHg after 20 weeks of gestation in previously normotensive women. PE was defined as de novo gestational hypertension with concurrent new onset proteinuria in a random urine sample with no evidence of urinary tract infection [32, 33]. HELLP syndrome was defined according to the class I and II
2006 Mississippi criteria (platelet count $\leq 100 \times 10^9/L$, aspartate transaminase (AST) or alanine-aminotransferase (ALT) $\leq 40$ IU/L and lactic acid dehydrogenase (LDH) $\geq 600$ IU/L) [34]. There were 293 cases of GH, 139 cases of PE, 14 cases of HELLP, and 45 cases which were classified as both PE and HELLP.

**Child cardiometabolic risk factors**

**Body mass index and ponderal index.** Information on early childhood height and weight was collected from the community health centres, which the children visited at the age of 2 months, 6 months, 12 months and 36 months. At the age of 6 years, all children were invited to the dedicated research facility in the Erasmus University Medical Centre, Sophia Children’s Hospital, for blood withdrawal and detailed measurements, among which height and weight measurements. Height and weight of children was measured according to standardized procedures: wearing underwear only, and height was measured in a barefooted standing position [30]. Body mass indexes (BMI’s) were calculated as weight/height$^2$. Sex- and age-adjusted standard deviation scores (SDS) of childhood BMI were calculated, based on Dutch reference growth charts (Growth Analyzer 4.0, Dutch Growth Research Foundation) [35]. Since ponderal index might be a better measure than BMI in infancy, sensitivity analyses by using the ponderal index were performed (weight/height$^3$) [36].

**Blood pressure.** Maternal systolic and diastolic blood pressure were measured at the visit to the research facility in late pregnancy, i.e. $\geq 25$ weeks of pregnancy. They were measured at
the right brachial artery, four times with one minute intervals, using the validated automatic sphygmanometer Datascope Accutor Plus TM (Paramus, NJ, USA) [37]. The mean value for systolic and diastolic blood pressure was calculated using the last three blood pressure measurements of each participant.

**Blood measurements.** A 30-minute fasting venous blood sample was obtained, in which total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides and insulin were measured.

**Fat mass index.** Body fat was measured by Dual-Energy X-ray absorptiometry (DXA) (iDXA, General Electrics–Lunar, 2008, Madison, WI, USA), according to standard procedures [38]. Previous studies have validated DXA against computed tomography for body fat assessment [39, 40]. Android fat mass was calculated as a percentage of total fat mass [39]. In order to obtain the fat mass index uncorrelated with height, total fat mass was divided by height$^3$, as confirmed by a log-log regression analysis [41, 42].

**Cardiometabolic clustering.** Clustering of cardiometabolic risk factors was defined as such when children had three or more of the following components: android fat mass percentage at the 75th centile or above, systolic or diastolic blood pressure at the 75th centile or above; high density lipoprotein cholesterol at the 25th centile or below or triglycerides at the 75th centile or above, and an insulin levels at the 75th centile or above [43].

**Pregnancy dating**

Gestational age is the most important determinant of fetal growth, so precise dating of the pregnancy is important. In accordance with clinical guidelines, if the gestational age was below 12 weeks and 5 days and the crown-rump length (CRL) measurement was smaller than 65 mm, pregnancy dating was performed using the first ultrasound measurement of the CRL. When the gestational age was older than 12 weeks and 5 days, or the biparietal diameter (BPD) was larger than 23 mm, pregnancy dating was performed using the BPD [44].

**Potential confounding variables**

Covariates in the regression models were selected based on their association with both the predictor and outcome of interest. Therefore, we conducted a Directed Acyclic Graph (DAG) analysis with a consensus meeting to identify which covariates were confounders ([**S1 Fig in S1 File**] [45, 46]. Consensus was achieved by the authors regarding the current structure of our regression models (DG, AP, BR, ES). The identified confounders consist of maternal BMI, ethnicity, glucose levels, educational level, smoking during pregnancy, alcohol use during pregnancy, gestational diabetes mellitus, and the child’s sex.

**Covariates**

Maternal age was assessed at the intake by questionnaire. Information on maternal education level, ethnicity, parity, folic acid supplementation, smoking and alcohol consumption was assessed by questionnaires during pregnancy [30]. Information on childhood sex, gestational age at birth, birth weight and length at birth was obtained from midwifery and (obstetric) medical records [44, 47]. At enrolment maternal weight (kg) and height (cm) were measured without shoes and heavy clothing after which pregnancy BMI (kg/m$^2$) was calculated. Weight measured at enrolment and pre-pregnancy weight were highly correlated (Pearson’s correlation coefficient 0.95 (P-value < 0.001)) [48].

Maternal glucose concentrations were measured in nonfasting blood samples which were collected at enrolment in the study. Glucose concentration (millimoles per litre) was measured with c702 module on the Cobas 8000 analyzer (Roche, Almere, the Netherlands). Information
on gestational diabetes mellitus was obtained from medical records after delivery. Gestational diabetes mellitus was diagnosed by a community midwife or an obstetrician according to Dutch midwifery and obstetric guidelines using the following criteria: either a random glucose level > 11.0 mmol/l (196 mg/dL), a fasting glucose ≥ 7.0 mmol/l (126 mg/dL) or a fasting glucose between 6.1 mmol/l (110 mg/dL) and 6.9 mmol/l (124 mg/dL) with a subsequent abnormal glucose tolerance test [49]. In clinical practice and for this study sample, an abnormal glucose tolerance test was defined as a glucose level greater than 7.8 mmol/l (140 mg/dL) after glucose intake.

Statistical analyses
Statistical analyses were performed using the Statistical Package of Social Sciences version 25.0 for Windows (IBM Corp., Armonk, NY, USA). A p-value < 0.05 was considered statistically significant. First, a non-response analysis was performed to compare baseline characteristics between women included and excluded from this study. Second, using Students two-tailed t-test and chi-square tests distribution of baseline characteristics and covariates within the study population were examined. Third, the associations of HDP with early childhood outcomes were examined using linear regression models: (1) a basic model including child’s sex and (2) a confounder model, which was additionally adjusted for maternal and early childhood covariates selected in the DAG analysis; maternal BMI, glucose levels, educational level, ethnicity, smoking during pregnancy, alcohol use during pregnancy and gestational diabetes mellitus. Linearity was tested by assessing distribution around a diagonal line within a residual-versus-predicted-plot. Effect modifications by maternal ethnicity, child’s sex, maternal smoking behaviours, maternal BMI were investigated. When significant interactions were present (p<0.1), stratified analyses were performed. Fourth, sensitivity analyses were performed. In the first analysis differences in early childhood cardiometabolic risk factors between pregnancies affected by 1) pre-eclampsia / HELLP, 2) GH or 3) ‘no HDP’ were tested using one-way ANOVA and Kruskal Wallis tests. To investigate the robustness of our results, sensitivity analyses defining cases as women with severe HDP (pre-eclampsia or HELLP) were performed. Lastly analysis to find differences in observed and expected values of confounders before and after imputation were conducted.

We constructed standard deviation scores (SDS) [(observed value—mean)/SD] for early childhood outcomes to enable comparison of effect estimates. The models were tested for multicollinearity using the tolerance statistic. As tolerance was > 0.20 for all variables in our models, multicollinearity was unlikely. Multiple imputation procedures for confounders with missing values, were performed, creating five imputed complete datasets. These were then pooled for analyses [50]. Missing values were pre-pregnancy BMI (19.6%), glucose levels (29.6%), educational level (9.3%), ethnicity (5.7%), smoking in pregnancy (12.7%), alcohol use during pregnancy (13.9%) and gestational diabetes mellitus (2.8%).

Results
Characteristics of the study population
Table 1 shows maternal and child characteristics of the total study population, and within the groups of women with and without HDP. In S1 Table in S1 File, offspring parameters according to the type of HDP that the mother experienced are demonstrated. In our study of 7794 women, 491 women (6.3%) developed a HDP. The majority of women had a normal pre-pregnancy BMI (median 22.7 kg/m2) and were non-smokers (72.5%). When investigating differences between maternal and child characteristics between women with a HDP and without a HDP, only BMI in children at 12 months of age was statistically different (mean BMI 17.47 kg/
m2 versus mean BMI 17.25 kg/m2 p-value 0.01). Systolic and diastolic blood pressure were higher in the HDP group (119.2 vs. 118.2 and 69.8 vs. 69.0, p-value 0.03 and 0.045 respectively), though differences were small. Non-response analysis showed that women included in this study were on average slightly younger (30.2 years vs. 30.6 years, p-value 0.02) and drank less alcohol (never used alcohol 50.6% vs. 51.1%, p-value < 0.001) compared to women excluded from the study. No differences were observed in pre-pregnancy BMI, educational level and ethnicity between women included and excluded from the analyses (S2 Table in S1 File).

### Early childhood cardiometabolic risk factors

Apart from a negative association between maternal HDP and BMI at 12 months, (confounder model: -0.15 SD, 95% CI -0.27; -0.03), no associations between maternal HDP and childhood BMI at 2, 6 or 36 months were present (Table 2). No differences in results were observed when we used the ponderal index as outcome measurement instead of BMI at 2, 6, 12 and 36 months (Table 2) [36]. Analyses with pulse as a different measure of common cardiometabolic risk factors, namely the sympatho-vagal balance, did not show different results (Table 2). The results did not change in sensitivity analyses with only pre-eclampsia and HELLP cases (S3 Table in S1 File).

At 6 years of age, no associations between maternal HDP and systolic blood pressure, diastolic blood pressure, BMI, fat mass index, cholesterol or triglyceride levels were observed. Results of interaction tests demonstrated that maternal HDP were inversely associated with triglyceride levels at 6 years of age, but only in girls (confounder model -0.28 SD, 95% CI -0.45;
The values of confounders for the regression analyses before and after multiple imputation did not show relevant differences (S4 Table in S1 File).

### Table 2. Associations between HDP and childhood cardiometabolic risk factors.

| Cardiometa bolic risk factor | Model | n | β (95% CI) | p-value | n | β (95% CI) | p-value |
|-----------------------------|-------|---|------------|---------|---|------------|---------|
|                             |       | HDP |            |         | Confounder |           |         |
| 2 months                    |       |     |            |         |             |         |
| BMI                         | 3779  | 235 (6.2%) | -0.06 (-0.19; 0.08) | 0.41 | 235 (6.2%) | -0.05 (-0.18; 0.09) | 0.50 |
| PI                          | 3779  | 235 (6.2%) | -0.09 (-0.24; 0.07) | 0.28 | 235 (6.2%) | -0.08 (-0.24; 0.07) | 0.31 |
| 6 months                    |       |     |            |         |             |         |
| BMI                         | 4518  | 267 (5.9%) | -0.11 (-0.23; 0.02) | 0.10 | 267 (5.9%) | -0.09 (-0.21; 0.04) | 0.17 |
| PI                          | 4518  | 267 (5.9%) | -0.13 (-0.25; -0.003) | 0.045 | 267 (5.9%) | -0.11 (-0.23; 0.02) | 0.09 |
| 12 months                   |       |     |            |         |             |         |
| BMI                         | 4614  | 283 (6.1%) | -0.16 (-0.28; -0.04) | 0.01 | 283 (6.1%) | -0.15 (-0.27; -0.03) | 0.02 |
| PI                          | 4614  | 283 (6.1%) | -0.17 (-0.29; -0.05) | 0.01 | 283 (6.1%) | -0.17 (-0.29; -0.05) | 0.01 |
| 36 months                   |       |     |            |         |             |         |
| BMI                         | 3933  | 263 (6.7%) | -0.03 (-0.16; 0.10) | 0.67 | 263 (6.7%) | -0.02 (-0.13; 0.13) | 0.97 |
| PI                          | 3933  | 263 (6.7%) | -0.09 (-0.22; 0.04) | 0.18 | 263 (6.7%) | -0.06 (-0.19; 0.07) | 0.35 |
| 6 years                     |       |     |            |         |             |         |
| BMI§                        | 5312  | 343 (6.5%) | 0.02 (-0.08; 0.12) | 0.71 | 343 (6.5%) | 0.03 (-0.07; 0.13) | 0.53 |
| Systolic blood pressure     | 4874  | 321 (6.6%) | 0.04 (-0.08; 0.15) | 0.50 | 321 (6.6%) | 0.05 (-0.07; 0.16) | 0.42 |
| Diastolic blood pressure    | 4874  | 321 (6.6%) | 0.09 (-0.02; 0.21) | 0.10 | 321 (6.6%) | 0.10 (-0.01; 0.21) | 0.09 |
| Fat mass index §            | 5163  | 330 (6.4%) | 0.03 (-0.08; 0.13) | 0.62 | 330 (6.4%) | 0.04 (-0.06; 0.14) | 0.42 |
| Cholesterol§                | 3531  | 241 (6.8%) | 0.01 (-0.12; 0.14) | 0.93 | 241 (6.8%) | 0.01 (-0.12; 0.14) | 0.87 |
| Triglycerides§              | 3523  | 239 (6.8%) | -0.10 (-0.23; 0.03) | 0.13 | 239 (6.8%) | -0.10 (-0.23; 0.03) | 0.14 |
| Pulse                       | 4873  | 347 (7.1%) | 1.10 (-0.09; 2.29) | 0.07 | 347 (7.1%) | 1.18 (-0.01; 2.37) | 0.05 |
| Cardiometabolic risk factor clustering | 3196  | 217 (6.8%) | 1.15 (0.97; 1.35) | 0.41 | 217 (6.8%) | 1.16 (0.84; 1.60) | 0.38 |

Abbreviations: BMI, body mass index; PI, ponderal index; HDP, hypertensive disorder of pregnancy. Values are regression coefficients (95% confidence interval) from (logistic) regression analyses that reflect the difference in childhood outcomes in SD scores, in pregnancies complicated by HDP versus pregnancies not complicated by HDP. Basic model was adjusted for child’s sex. Confounder model includes maternal pre-pregnancy body mass index, educational level, ethnicity, smoking during pregnancy, alcohol use during pregnancy, maternal glucose levels and presence of gestational diabetes mellitus. Variables were log transformed.

https://doi.org/10.1371/journal.pone.0261351.t002

Table 3. HDP and childhood cardiometabolic risk factors at 6 years of age, split for child’s sex.

| Cardiometa bolic risk factor | Model | Boys (N = 3952) | p-value | Girls (N = 3842) | p-value |
|-----------------------------|-------|----------------|---------|----------------|---------|
|                             |       | n | β (95% CI) |         | n | β (95% CI) |         |
| Fat mass index §            | Basic | 2568 | 0.09 (-0.06; 0.25) | 0.23 | 2594 | -0.04 (-0.18; 0.11) | 0.64 |
|                             | Confounder | 2568 | 0.12 (-0.02; 0.27) | 0.09 | 2594 | -0.03 (-0.17; 0.11) | 0.66 |
| Cholesterol§                | Basic | 1798 | 0.15 (-0.04; 0.33) | 0.12 | 1733 | -0.12 (-0.30; 0.07) | 0.20 |
|                             | Confounder | 1798 | 0.16 (-0.03; 0.34) | 0.09 | 1733 | -0.12 (-0.30; 0.07) | 0.23 |
| Triglycerides§              | Basic | 1796 | 0.09 (-0.11; 0.28) | 0.38 | 1727 | -0.27 (-0.45; -0.09) | 0.003 |
|                             | Confounder | 1796 | 0.09 (-0.10; 0.28) | 0.36 | 1727 | -0.28 (-0.45; -0.10) | 0.002 |

Abbreviations: HDP, hypertensive disorder of pregnancy. Values are (logistic) regression coefficients (95% confidence interval) that reflect the difference in early childhood outcomes in SD scores, in pregnancies complicated by HDP versus pregnancies not complicated by HDP. Basic model was adjusted for child’s sex. The confounder model includes maternal pre-pregnancy body mass index, educational level, ethnicity, smoking during pregnancy, alcohol use during pregnancy, maternal glucose levels and gestational diabetes mellitus. Variables were log transformed.

https://doi.org/10.1371/journal.pone.0261351.t003
Discussion

Principal findings

In this study, no strong and independent associations between maternal hypertensive disorders of pregnancy and early childhood cardiometabolic risk factors were observed. A negative association between maternal HDP and offspring BMI at the age of 12 months was observed, however this was no longer present at 2 and 6 years of age.

Results

Differences in systolic and diastolic blood pressure between the groups of women with and without a HDP were small. Moreover, mean blood pressures in the HDP group were relatively low. This could be explained by the fact that maternal blood pressure was measured in late pregnancy, i.e. ≥25 weeks of gestation. Thereby, the onset of a HDP could be (long) after the blood pressure measurement at the Generation R study research facility. Then, the blood pressure measurement in Table 1 does not reflect blood pressure at the time of diagnosis. Second, a woman may be hospitalized due to a HDP, before she could attend the Generation R research facility: then her blood pressure measurement was missing. Lastly, the relatively low blood pressure could be due to the heterogeneity of the HDP group. Since hypertension isn’t one of the criteria to diagnose ‘HELLP syndrome’, the women with HELLP in the HDP group do not increase the mean systolic or diastolic blood pressure.

In earlier studies, maternal HDP has been associated with a lower BMI in the offspring [7, 9]. However, data are inconsistent and associations with higher BMI have also been demonstrated [51]. Additionally, in literature, associations of PE with offspring BMI became inverse after adjustment for potential confounding factors, with maternal pre-pregnancy BMI as the main covariate attributable to this change [7]. In our analyses, inverse associations were already present in the basic analyses, before adjusting for maternal pre-pregnancy BMI. This is possibly due to the small differences in BMI between women with and without a HDP in our study population.

Our findings are in line with the results of a previous study in the same cohort as the current study. That previous study demonstrated a strong association between an adverse maternal cardiometabolic profile and an adverse cardiometabolic profile in their offspring. Moreover, they demonstrated that this association was not attenuated by pregnancy complications such as preeclampsia [52]. This endorses that the effect of PE on the offspring cardiometabolic profile is only limited.

Similar to two other studies, we found no association between maternal HDP and offspring blood pressure [53]. This may in part be explained by the challenges of obtaining a reliable

Table 4. HDP and early childhood cardiometabolic risk factors at 6 years of age, split for maternal pre-pregnancy BMI.

| Cardiometabolic risk factor | Model     | <18.5 (N = 315) | 18.5–25.0 (N = 5280) | >25.0 (N = 2223) |
|----------------------------|-----------|-----------------|---------------------|------------------|
|                            | β (95% CI)| p-value         | β (95% CI)          | p-value          |
| BMI                        | Basic     | 0.05 (-0.45; 0.54) | 0.86               | -0.05 (-0.17; 0.08) | 0.44          |
|                            | Confounder| 0.20 (-0.02; 0.42) | 0.08               | 0.20 (-0.02; 0.41) | 0.07          |

Abbreviations: HDP, hypertensive disorder of pregnancy; BMI, body mass index. Values are regression coefficients (95% confidence interval) that reflect the difference in early childhood outcomes in SD scores, in pregnancies complicated by HDP versus pregnancies not complicated by HDP. Basic model was adjusted for child’s sex. Confounder model includes educational level, ethnicity, smoking during pregnancy, alcohol use during pregnancy, maternal glucose levels and gestational diabetes mellitus.

https://doi.org/10.1371/journal.pone.0261351.t004
blood pressure measurement in young children. Since a physiologic childhood blood pressure has a smaller physiologic range compared to the adult blood pressure, it is harder to detect a (statistically significant) association with blood pressure in childhood. To address this point, the child’s pulse was added to our outcome measures. This measure is more variable, but this did not change the results.

Next, the presence of maternal HDP was found to be inversely associated with offspring triglyceride levels, but only in girls. In literature, sex differences in the lipid profile in healthy adults have been described. It is known that since sex hormones have the ability to modulate the lipid metabolism [54–56]. Additionally, an animal study demonstrated that in mice, PE led to sex-specific metabolomic differences in the offspring: the female fetuses showed pronounced alterations in the lipid metabolism [57]. More specifically, lipid metabolite levels that were associated with triglyceride storage were lower in the female fetuses in comparison to the male fetuses, which is in line with our findings. These sex-specific differences are proposed to be due to the significantly decreased expression of lipid transporters and lipid binding proteins in the female placentas that were exposed to PE [57]. For lipids other than triglycerides, no significant differences in the offspring were observed when comparing pregnancies complicated by a HDP and pregnancies not complicated by a HDP, which is also in line with previously published studies [13, 26, 28, 29, 58].

Many studies demonstrate that the associations between maternal HDP and cardiometabolic health in the offspring are mediated by adverse birth outcomes such as preterm birth and low birth weight [59, 60]. This amplified cardiometabolic risk, attributable to fetal growth restriction and preterm birth, is not limited to childhood but is demonstrated to persist into adulthood [61, 62]. Since no significant associations between HDP and cardiometabolic risk factors in the offspring were found in our first models, no mediation analyses with adverse birth outcomes such as preterm birth and low birth weight were performed.

Research implications

It is required to further explore the underlying mechanisms between maternal HDP and long term cardiometabolic health in the offspring. With help of metabolomics studies, the role of shared lifestyle related factors could be elucidated in the development of both hypertensive disorders and offspring cardiometabolic risk factors.

Strengths and limitations

The main strengths of our study are the large sample size, the prospective design of the study and the standardized procedures that were used for data collection. Moreover, this study is one of few studies to assess the associations of maternal HDP with fat mass percentage and lipid levels as measures of cardiometabolic health in early childhood [63]. In contrast, previous studies examining cardiometabolic health in offspring from women with a HDP mainly focused on BMI and blood pressure [8, 64].

Some limitations of this study also need to be addressed. First, follow-up data with regard to cardiometabolic outcomes in childhood varied from 41% to 68%. Especially response rates for measures from blood sampling (e.g. cholesterol) are lower compared to BMI measures. This may have contributed to selection bias. Second, the children in this study are relatively young and therefore large differences in cardiometabolic risk factors were not to be expected. This small variation in outcome measures makes it harder to detect statistically significant associations. Third, new guidelines state that PE is diagnosed based on the presence of de novo hypertension after 20 weeks gestation accompanied by one of the following: proteinuria, acute kidney injury, liver dysfunction, neurological features, haemolysis or thrombocytopenia, or
fetal growth restriction [1, 65]. However, in our data we could only determine the presence of de novo hypertension, proteinuria and fetal growth restriction, possibly leading to misclassification of cases. To classify HDP by severity as best as possible, PE and HELLP was separated from GH [31, 66]. Fourth, even after adjusting for a large number of potential confounders, residual confounding may still be present in the observed associations. Examples of residual confounding could include lifestyle-related characteristics such as maternal (prenatal) physical activity. Finally, the majority of women in the study population were relatively young and had a low-risk profile. Moreover, in the groups of women both affected and unaffected by HDP, the mean gestational age at birth was at term. This implies relatively mild cases of HDP within this study population. As a result, the generalizability of the findings in this study is limited.

Conclusions
In this large, prospective, population-based cohort study, no strong and persistent associations between maternal HDP and cardiometabolic risk factors in the offspring between 2 months and 6 years of age were observed. Apart from small and favourable changes in BMI and triglycerides at some of the time points, the effects of maternal HDP on child cardiometabolic risk factors seem relatively minor. This however does not rule out effects on cardiometabolic health in the offspring in later life.

Supporting information
S1 File.
(DOCX)

Acknowledgments
We gladly acknowledge the participation of all participants and the contribution of the general practitioners, hospitals, midwives, and the pharmacies in Rotterdam and all those concerned in the Generation R Study. The Generation R Study was conducted by the Erasmus Medical Centre, Rotterdam, The Netherlands, in close collaboration with the School of Law and the Faculty of Social Sciences of Erasmus University, Rotterdam, The Netherlands. Furthermore, we gratefully acknowledge Municipal Health Service, Rotterdam area; the Rotterdam Homecare Foundation; the Stichting Trombosedienst and Arts laboratorium Rijnmond, Rotterdam.

Author Contributions
Conceptualization: Dionne V. Gootjes, Anke G. Posthumus, Vincent W. V. Jaddoe, Bas B. van Rijn, Eric A. P. Steegers.
Data curation: Dionne V. Gootjes.
Formal analysis: Dionne V. Gootjes.
Funding acquisition: Vincent W. V. Jaddoe, Eric A. P. Steegers.
Investigation: Dionne V. Gootjes.
Methodology: Dionne V. Gootjes, Anke G. Posthumus, Bas B. van Rijn.
Project administration: Vincent W. V. Jaddoe, Eric A. P. Steegers.
Supervision: Vincent W. V. Jaddoe, Bas B. van Rijn, Eric A. P. Steegers.
Writing – original draft: Dionne V. Gootjes.
Writing – review & editing: Anke G. Posthumus, Vincent W. V. Jaddoe, Bas B. van Rijn, Eric A. P. Steegers.

References

1. American College of O, Gynecologists, Task Force on Hypertension in P. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122(5):1122–31. https://doi.org/10.1097/AOG.0b013e31827382.03963.88 PMID: 24150027.

2. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC pregnancy and childbirth. 2009; 9:8–. https://doi.org/10.1186/1471-2393-9-8 PMID: 19245695.

3. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saîo S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018; 72(1):24–43. https://doi.org/10.1161/HYPTENSIONAH.117.10803 PMID: 29899139.

4. Benschop L, Duvekot JJ, Roeters van Lennep JE. Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy. Heart. 2019; 105(16):1273–8. https://doi.org/10.1136/heartjnl-2018-313453 PMID: 31175138.

5. van Rijn BB, Nijdam ME, Bruins e HW, Roest M, Uiterwa al CS, Grobbee DE, et al. Cardiovascula r disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol. 2013; 121(5):1040–8. Epub 2013/05/03. https://doi.org/10.1097/AOG.0b013e31828ea3b5 0006250-201305000-00019 [pii]. PMID: 23635741.

6. Zoet GA, Linstra KM, Bernsen MLE, Koster MPH, van der Schaaf IC, Kappelle LJ, et al. Stroke after pregnancy disorders. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017; 215:264–6. https://doi.org/10.1016/j.ejogrb.2017.06.018.

7. Tripathi RR, Rífas-Shiman SL, Hawley N, Hivert MF, Oken E. Hypertensive Disorders of Pregnancy and Offspring Cardiometabolic Health at Midchildhood: Project Viva Findings. J Am Heart Assoc. 2018; 7(3). https://doi.org/10.1161/JAHA.116.003264.

8. Byberg KK, Oymar K, Eide GE, Forman MR, Julliusson PB. Exposure to preeclampsia in utero affects growth from birth to late childhood dependent on child’s sex and severity of exposure: Follow-up of a nested case-control study. PLoS One. 2017; 12(5):e0176627. Epub 2017/05/10. https://doi.org/10.1371/journal.pone.0176627 PONE-D-16-37520 [pii]. PMID: 28468480; PubMed Central PMCID: PMCS423584.

9. Geelhoed JJM, Fraser A, Tilling K, Benfield L, Davey Smith G, Sattar N, et al. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and Children. Circulation. 2010; 122(12):1192–9. Epub 2010/09/07. https://doi.org/10.1161/CIRCULATIONAHA.110.936674 PMID: 20823385.

10. Miliku K, Bergen NE, Bakker H, Hofman A, Steegers EAP, Gaillard R, et al. Associations of Maternal and Paternal Blood Pressure Patterns and Hypertensive Disorders during Pregnancy with Childhood Blood Pressure. Journal of the American Heart Association. 2016; 5(10):e003884. https://doi.org/10.1161/JAHA.116.003884 PMID: 27742617.

11. Zhang M, Michos ED, Wang G, Wang X, Mueller NT. Associations of Cord Blood Vitamin D and Preeclampsia With Offspring Blood Pressure in Childhood and Adolescence. JAMA Network Open. 2020; 3(10):e2019046–6. https://doi.org/10.1001/jamanetworkopen.2020.19046 PMID: 33017029.

12. Pruthi D, Khankin EV, Blanton RM, Aronovitz M, Burke SD, McCurley A, et al. Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. Hypertension. 2015; 65(4):863–70. https://doi.org/10.1161/HYPTENSIONAH.114.04971 PMID: 25712723.

13. Lazdam M, de la Horra A, Pitcher A, Mannie Z, Diesch J, Trevitt C, et al. Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism? Hypertension. 2010; 56(1):159–65. https://doi.org/10.1161/HYPTENSIONAH.110.150235 PMID: 20479334.

14. Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? American journal of human genetics. 1962; 14:353–62. PMID: 13937884.

15. Tounian P. Programming towards childhood obesity. Ann Nutr Metab. 2011; 58 Suppl 2:30–41. Epub 2011/08/24. 000328038 [pii]. https://doi.org/10.1159/000328038 PMID: 21849979.

16. Santos S, Severo M, Gaillard R, Santos AC, Barros H, Oliveira A. The role of prenatal exposures on body fat patterns at 7 years: Intrauterine programming or birthweight effects? Nutr Metab Cardiovasc Dis. 2016; 26(11):1004–10. https://doi.org/10.1016/j.numecd.2016.06.010 PMID: 27461861.
17. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 2004; 111(3):200–6. Epub 2004/02/14. https://doi.org/10.1111/j.1471-0528.2004.00042.x PMID: 14961879.

18. Alsnes IV, Vatten LJ, Fraser A, Bjorngaard JH, Rich-Edwards J, Romundstad PR, et al. Hypertension in Pregnancy and Offspring Cardiovascular Risk in Young Adulthood: Prospective and Sibling Studies in the HUNT Study (Nord-Trondelag Health Study) in Norway. Hypertension. 2017; 69(4):591–8. Epub 2017/02/23. HYPERTENSIONAHA.116.08414 [pii] https://doi.org/10.1161/HYPERTENSIONAHA.116.08414 PMID: 28226467.

19. Goffin SM, Derraik JGB, Groom KM, Cutfield WS. Maternal pre-eclampsia and long-term offspring health: Is there a shadow cast? Pregnancy Hypertens. 2018; 12:11–5. Epub 2018/04/21. S2210-7789(17)30447-6 [pii] https://doi.org/10.1016/j.preghy.2018.02.003 PMID: 29674189.

20. Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers who had preeclampsia: a population-based cohort study. American Journal of Obstetrics and Gynecology. 2009; 201(3):268.e1–e10. https://doi.org/10.1016/j.ajog.2009.06.060 PMID: 19733276.

21. Koopmans CM, Bijlenga D, Groen H, Vijgen SMC, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. The Lancet. 2009; 374(9694):979–88. https://doi.org/10.1016/S0140-6736(09)60736-4 PMID: 19656558.

22. Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. American Journal of Obstetrics and Gynecology. 2006; 195(6):1557–63. https://doi.org/10.1016/j.ajog.2006.05.021 PMID: 17014813.

23. Adair LS, Fall CH, Osmond C, Stein AD, Martorell R, Ramirez-Zea M, et al. Associations of linear growth and relative weight gain during early life with adult health and human capital in countries of low and middle income: findings from five birth cohort studies. Lancet. 2013; 382(9891):525–34. https://doi.org/10.1016/S0140-6736(13)60103-8 PMID: 23534981.

24. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008; 117(25):3171–80. Epub 2008/06/19. CIRCULATIONAHA.107.730366 [pii] https://doi.org/10.1161/CIRCULATIONAHA.107.730366 PMID: 18559702; PubMed Central PMCID: PMC3568631.

25. Tenhola S, Rahiala E, Martikainen E, Halonen P, Vuotilainen R. Blood pressure, serum lipids, fasting insulin, and adrenal hormones in 12-year-old children born with maternal preeclampsia. J Clin Endocrinol Metab. 2003; 88(3):1217–22. https://doi.org/10.1210/jc.2002-020903 PMID: 12629109.

26. Miettola S, Hartikainen A-L, Vääräsmäki M, Bloigu A, Ruokonen A, Järvelin M-R, et al. Offspring’s blood pressure and metabolic phenotype after exposure to gestational hypertension in utero. European Journal of Epidemiology. 2013; 28(1):87–98. https://doi.org/10.1007/s10654-013-9763-5 PMID: 23354981.

27. Alsnes IV, Janszky I, Forman MR, Vatten LJ, Økland I. A population-based study of associations between preeclampsia and later cardiovascular risk factors. American Journal of Obstetrics and Gynecology. 2014; 211(6):657.e1–e7. https://doi.org/10.1016/j.ajog.2014.06.026 PMID: 24949538.

28. Lawlor DA, Macdonald-Wallis C, Fraser A, Nelson SM, Hingorani A, Davey Smith G, et al. Cardiovascular biomarkers and vascular function during childhood in the offspring of mothers with hypertensive disorders of pregnancy: findings from the Avon Longitudinal Study of Parents and Children. European Heart Journal. 2011; 32(3):335–45. https://doi.org/10.1093/eurheartj/ehr300 PMID: 21862461.

29. Kooijman MN, Krithoff CJ, van Duijn CM, Duijts L, Franco OH, van IMH, et al. The Generation R Study: design and cohort update 2017. Eur J Epidemiol. 2016; 31(12):1243–64. Epub 2017/01/11. https://doi.org/10.1007/s10654-016-0224-9 [pii] PMID: 28070760; PubMed Central PMCID: PMC5233749.

30. Coolman M, de Groot CJ, Jaddoe VW, Hofman A, Raat H, Steegers EA. Medical record validation of maternally reported history of preeclampsia. J Clin Epidemiol. 2010; 63(8):932–7. Epub 2010/03/02. S0895-4356(09)00368-0 [pii] https://doi.org/10.1016/j.clinepi.2009.10.010 PMID: 20189760.

31. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001; 20(1):IX–XIV. Epub 2002/06/05. https://doi.org/10.1081/PRG-100104165 [pii] PMID: 12044323.

32. Bulletins—Obstetrics ACoP. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002; 99(1):159–67. Epub 2005/09/24. https://doi.org/10.1016/s0029-7844(01)01747-1 PMID: 16175681.
34. Martin JN Jr., Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006; 195(4):914–34. Epub 2006/04/25. S0002-9378(05)01367-0 [pii] https://doi.org/10.1016/j.ajo.2005.08.044 PMID: 16631593.

35. Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP. Body index measurements in 1996–7 compared with 1980. Arch Dis Child. 2000; 82(2):107–12. Epub 2000/01/29. https://doi.org/10.1136/adc.82.2.107 PMID: 10648362; PubMed Central PMCID: PMC1718204.

36. Sweeting HN. Measurement and definitions of obesity in childhood and adolescence: a field guide for the uninitiated. Nutr J. 2007; 6:32. https://doi.org/10.1186/1475-2916-6-32 PMID: 17963490.

37. Wong SN, Tz Sung RY, Leung LC. Validation of three oscillometric blood pressure devices against auscultatory mercury sphygmomanometer in children. Blood Press Monit. 2006; 11(5):281–91. Epub 2006/08/26. https://doi.org/10.1097/01.mbp.0000209082.09623.b4 00126097-200610000-00006 [pii]. PMID: 16932037.

38. Gishti O, Gaillard R, Manniesing R, Abrahamse-Berkved M, van der Beek EM, Happe DH, et al. Fetal and infant growth patterns associated with total and abdominal fat distribution in school-age children. J Clin Endocrinol Metab. 2014; 99(7):2557–66. Epub 2014/04/10. https://doi.org/10.1210/jc.2013-4345 PMID: 24712569.

39. Helba M, Binkovitz LA. Pediatric body composition analysis with dual-energy X-ray absorptiometry. Pediatr Radiol. 2009; 39(7):647–56. Epub 2009/05/06. https://doi.org/10.1007/s00247-009-1247-0 PMID: 19415261.

40. Shuster A, Patlas M, Pirnouskas JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012; 85(1009):1–10. Epub 2011/09/23. 38447238 [pii] https://doi.org/10.1259/bjr/38447238 PMID: 21937614; PubMed Central PMCID: PMC3473928.

41. Wells JC, Cole TJ, steam As. Adjustment of fat-free mass and fat mass for height in children aged 8 y. Int J Obes Relat Metab Disord. 2002; 26(7):947–52. Epub 2002/06/25. https://doi.org/10.1038/sjijo.0802027 PMID: 12080448.

42. Santos S, Gaillard R, Oliveira A, Barros H, Abrahamse-Berkved M, van der Beek EM, et al. Associations of Infant Subcutaneous Fat Mass with Total and Abdominal Fat Mass at School-Age: The Generation R Study. Paediatr Perinat Epidemiol. 2016; 30(5):511–20. Epub 2016/05/27. https://doi.org/10.1111/ppe.12307 PMID: 27225335; PubMed Central PMCID: PMC5496673.

43. Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, et al. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2009; 119(4):628–47. Epub 2009/01/14. CIRCULATION-NAHA.108.191394 [pii] https://doi.org/10.1161/CIRCULATIONAHA.108.191394 PMID: 19139390.

44. Verburg BO, Steegers EA, De Ridder M, Snijders RJ, Smith E, Hofman A, et al. New charts for ultrasound dating of pregnancy and assessment of fetal growth: longitudinal data from a population-based cohort study. Ultrasound Obstet Gynecol. 2008; 31(4):388–96. Epub 2008/03/19. https://doi.org/10.1002/uog.5225 PMID: 18348183.

45. Textor J, van der Zande B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. Int J Epidemiol. 2016; 45(6):1887–94. https://doi.org/10.1093/ije/dyw341 PMID: 28089956.

46. VanderWeele TJ, Hernan MA, Robins JM. Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology. 2008; 19(5):1877–94. https://doi.org/10.1093/epi0802027 PMID: 18633311.

47. Niskasuo A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand. 1991; 80(8–9):756–62. Epub 1991/08/01. https://doi.org/10.1111/j.1651-2227.1991.tb11945.x PMID: 1957592.

48. Gaillard R, Durmus B, Hofman A, Mackenbach JP, Steegers EA, Jaddoe VW. Risk factors and outcomes of maternal obesity and excessive weight gain during pregnancy. Obesity (Silver Spring). 2013; 21(5):1046–55. Epub 2013/06/21. https://doi.org/10.1002/oby.20088 PMID: 23784909.

49. Silva L. Fetal Origins of Socioeconomic Inequalities in Early Childhood Health: the Generation R Study [Ph.D. thesis]: Erasmus University Rotterdam; 2009.

50. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009; 338:b2393. Epub 2009/07/01. https://doi.org/10.1136/bmj.b2393 PMID: 19564179; PubMed Central PMCID: PMC2714692.

51. Patro Golab B, Santos S, Voerman E, Lawlor DA, Jaddoe VVW, Gaillard R, et al. Influence of maternal obesity on the association between common pregnancy complications and risk of childhood obesity; an
individual participant data meta-analysis. Lancet Child Adolesc Health. 2018; 2(11):812–21. Epub 2018/09/07. https://doi.org/10.1016/S2352-4642(18)30273-6 PMID: 30201470.

52. Benschop L, Schalekamp-Timmermans S, Roeters van Lennep JE, Jaddoe VWV, Steegers EAP, Ikram MK. Cardiovascular Risk Factors Track From Mother to Child. J Am Heart Assoc. 2018; 7(19): e009536. https://doi.org/10.1016/j.ahajournal.2018.06.016 PMID: 30070757.

53. Thoulass JC, Robertson L, Denadai L, Crilly M, Iversen L, et al. Hypertensive disorders of pregnancy and adult offspring cardiometabolic outcomes: a systematic review of the literature and meta-analysis. J Epidemiol Community Health. 2016; 70(4):414–22. https://doi.org/10.1136/jech-2015-205483 PMID: 26347276.

54. Seidell JC, Cigolini M, Charzewiska J, Ellsinger BM, Bjorntorp P, Hautvast JG, et al. Fat distribution and gender differences in serum lipids in men and women from four European communities. Atherosclerosis. 1991; 87(2–3):203–10. https://doi.org/10.1016/0021-9150(91)90022-u PMID: 1854366.

55. Vaidya D, Dobs A, Gapstur SM, Golden SH, Hankinson A, Liu K, et al. The association of endogenous sex hormones with lipoprotein subclass distribution in the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2008; 57(6):782–90. Epub 2008/05/27. S0026-0495(08)00052-8 [pii] https://doi.org/10.1016/j.metabol.2008.01.019 PMID: 18502260; PubMed Central PMCID: PMC4017356.

56. Johnson JL, Slentz CA, Duscha BD, Samsa GP, McCartney JS, Hournard JA, et al. Hypertensive disorders of pregnancy and adult offspring cardiometabolic outcomes: a systematic review of the literature and meta-analysis. J Epidemiol Community Health. 2018; 72(2):371–7. https://doi.org/10.1136/jech-2017-207668 PMID: 28889508.

57. Stojanovska V, Dijkstra DJ, Vogtman R, Gellhaus A, Scherjon SA, Plošč T. A double hit preeclampsia model results in sex-specific growth restriction patterns. Disease Models & Mechanisms. 2019; dmm.035980. https://doi.org/10.1242/dmm.035980 PMID: 30683649.

58. Seppälä S, Voutilainen R, Tenhola S. Markers of Insulin Sensitivity in 12-Year-Old Children Born from Preeclamptic Pregnancies. The Journal of Pediatrics. 2015; 167(1):125–30. https://doi.org/10.1016/j.jpeds.2015.04.015 PMID: 25962933.

59. Thomas C, Hypponen E, Power C. Prenatal exposures and glucose metabolism in adulthood: are effects mediated through birth weight and adiposity? Diabetes Care. 2007; 30(4):918–24. https://doi.org/10.2337/dc06-1881 PMID: 17277041.

60. Ramirez-Velez R, Correa-Bautista JE, Villa-Gonzalez E, Martinez-Torres J, Hackney AC, Garcia-Hermos A. Effects of preterm birth and fetal growth retardation on life-course cardiovascular risk factors among schoolchildren from Colombia: The FUPRECOL study. Early Hum Dev. 2017; 106–107:53–8. Epub 2017/02/15. S0378-3782(16)30552-7 [pii] https://doi.org/10.1016/j.earlhumdev.2017.02.001 PMID: 28193574.

61. Sipola-Leppänen M, Väläräsmäki M, Tikanmäki M, Matinolli H-M, Miettola S, Holvi P, et al. Cardiometabolic Risk Factors in Young Adults Who Were Born Preterm. American Journal of Epidemiology. 2015; 181(11):861–73. https://doi.org/10.1093/aje/kwu443 PMID: 25947956.

62. Markopoulou P, Papanikolaou E, Analytis A, Zoumakis E, Siahanidou T, Preterm Birth as a Risk Factor for Metabolic Syndrome and Cardiovascular Disease in Adult Life: A Systematic Review and Meta-Analysis. J Pediatr. 2019; 210:69–80 e5. Epub 2019/04/18. S0022-3476(19)30273-2 [pii] https://doi.org/10.1016/j.jpeds.2019.02.041 PMID: 30992219.

63. Saito Y, Takahashi O, Arioka H, Kobayashi D. Associations between body fat variability and later onset of cardiovascular disease risk factors. PloS one. 2017; 12(4):e0175057–e. https://doi.org/10.1371/journal.pone.0175057 PMID: 28369119.

64. Miliku K, Berger NE, Bakker H, Hofman A, Steegers EA, Gaillard R, et al. Associations of Maternal and Paternal Blood Pressure Patterns and Hypertensive Disorders during Pregnancy with Childhood Blood Pressure. J Am Heart Assoc. 2016; 5(10). Epub 2016/10/16. JAHA.116.003884 [pii] https://doi.org/10.1161/JAHA.116.003884 PMID: 27742617; PubMed Central PMCID: PMC5121490.

65. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens. 2008; 26(2):295–302. https://doi.org/10.1097/HJH.0b013e3282f1a953 PMID: 18192844.

66. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The hypertensive disorders of pregnancy: ISHSP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018; 13:291–310. https://doi.org/10.1016/j.preghy.2018.05.004 PMID: 29803330.